Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

EViT-UNET: U-Net Like Efficient Vision Transformer for Medical Image Segmentation on Mobile and Edge Devices
Li, Xin , Zhu, Wenhui , Dong, Xuanzhao, Dumitrascu, Oana M. , Dong, Xuanzhao, Wang, Yalin

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10981108 | PMID 40791942 Get It

TPOT: Topology Preserving Optimal Transport in Retinal Fundus Image Enhancement
Dong, Xuanzhao, Zhu, Wenhui , Li, Xin , Sun, Guoxin , Dumitrașcu, Oana , Dong, Xuanzhao, Su, Yi, Wang, Yalin

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10981104 | PMID 40881625 Get It

IPMN Risk Assessment Under Federated Learning Paradigm
Pan, Hongyi , Hong, Ziliang , Keleş, Elif , Aktas, Halil Ertugrul , Taktak, Yavuz , Medetalibeyoğlu, Alpay , Zhang, Zheyuan , Velichko, Yury , Schoots, Ivo G. , Bruno, Marco J. , Tiwari, Pallavi , Bolan, Candice W. , Gonda, Tamas A. , Miller, Frank, Keswani, Rajesh N. , Miller, Frank H. , Miller, Frank H , Velichko, Yuri S , Durak, Görkem , Spampinato, Concetto , Tiwari, Pallavi , Wallace, Michael B. , Xu, Ziyue , Bağcı, Ulaş

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10980733 Get It

Rizatriptan vs Placebo for Attacks of Vestibular Migraine
Eggers, Scott D.Z. , Jen, Joanna C. , Geske, Jennifer R. , Hofschulte, Deanna R., Gonzalez, Gabrielle F , Neff, Brian A., Shepard, Neil T., McCaslin, Devin L. , Baloh, Robert W., Geske, Jennifer , Staab, Jeffrey P. , LeMahieu, Allison , Liu, Honghu

JAMA Neurology | May 12, 2025 | Volume: 82 | Issue: 7 | Pages: 676

10.1001/jamaneurol.2025.1006 | PMID 40354049 Get It

ImportanceVestibular migraine has no established treatments.ObjectiveTo test the efficacy of rizatriptan for treating vestibular migraine attacks.Design, Setting, and ParticipantsThis double-blind, randomized clinical trial of rizatriptan vs placebo was conducted from December 2014 through July 2020 (data analyses in 2021 and sensitivity analyses in 2022 and 2024) at 2 tertiary neurotologic centers. Adults with vestibular migraine were included.InterventionAll participants underwent prospective observation to confirm diagnosis and illness activity and were then randomized in a 2:1 ratio to receive rizatriptan 10 mg or placebo to treat up to 3 vestibular migraine attacks per participant.Main Outcomes and MeasuresParticipants rated symptoms as absent, mild, moderate, or severe at scheduled intervals. Primary outcomes were the percentage of attacks with reductions in vertigo and unsteadiness/dizziness from moderate or severe to absent or mild at 1 hour. Secondary outcomes were the percentage of attacks with complete resolution of vestibular symptoms at 1 hour; reductions in headache and associated symptoms at 1 hour; use of rescue medications after 1 hour; reductions in vestibular, headache, and associated symptoms at 24 hours without rescue medications; treatment satisfaction and quality of life at 48 hours; and rates of serious adverse effects and discontinuation due to adverse effects.ResultsOf 222 total participants (mean [SD] age, 42.3 [11.7] years; 70.7% were women), 134 (60.4%) with active illness treated 307 attacks. Efficacy was tested using 240 attacks with vestibular symptoms rated as moderate or severe when participants took study drug. At 1 hour, rizatriptan did not differ from placebo for reducing vertigo (73/151 [48.3%] vs 50/88 [56.8%] attacks; odds ratio [OR], 0.71 [95% CI, 0.42-1.21]), unsteadiness/dizziness (29/151 [19.2%] vs 11/89 [12.4%] attacks; OR, 1.69 [95% CI, 0.80-3.57]), or any secondary outcomes. Similar percentages of participants in rizatriptan and placebo groups (26.4% for both groups) added rescue remedies after 1 hour. At 24 hours, rizatriptan had medium effects over placebo for unsteadiness/dizziness (OR, 2.65) and motion sensitivity (OR, 3.58). Post hoc analyses of all treated attacks found a medium effect favoring rizatriptan for headache and photophobia or phonophobia at 24 hours. Treatment satisfaction was equivocal. Quality of life was mixed. No participants experienced serious adverse effects or discontinued treatment for adverse effects.Conclusions and RelevanceIn this study, rizatriptan was ineffective at 1 hour for treating vestibular migraine attacks and had limited benefit on symptoms at 24 hours. Findings do not support using rizatriptan for vestibular migraine attacks.Trial RegistrationClinicalTrials.gov Identifier: NCT02447991
Epilepsy at Precision Medicine Crossroads—Disease Modification, Presymptomatic Treatment, and Early Screening
Brunklaus, Andreas , Lal, Dennis , Brunklaus, Andreas , Ivaniuk, Alina , Pestana‐Knight, Elia

JAMA Neurology | May 12, 2025 | Volume: 82 | Issue: 10 | Pages: 975

10.1001/jamaneurol.2025.1179 | PMID 40354070 Get It

This Viewpoint describes the benefits and challenges of integrating genomic information with disease-modifying therapies for epilepsy.
AAN 2025 Interview: Joseph Sirven
Sirven, Joseph

American Medical Journal Neurology | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/neurolamj/xrfw4394 Get It

The formal EU-US Meniscus Rehabilitation 2024 Consensus. An ESSKA-AOSSM-AASPT Initiative. Part I –Rehabilitation Management After Meniscus Surgery (Meniscectomy, Repair, Reconstruction)
Pujol, Nicolas , Giordano, Airelle O., Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J., Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Piontek, Tomasz , Schmitt, Laura C. , Benjamin, C., Irrgang, James J. , Rambaud, Alexandre , Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Pujol, Nicolas , Giordano, Airelle O., Wong, Stephanie E. , Becker, Roland, Villa, Francesco Della, Klugarová, Jitka , Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Rambaud, Alexandre, Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Prill, Robert

International Journal of Sports Physical Therapy | May 12, 2025 | Volume: 20 | Issue: 6 | Pages: No page available

10.26603/001c.137095 Get It

Purpose The aim of part-one of this EU-US consensus was to combine literature research and expertise to provide recommendations for the usage of rehabilitation (including physical therapy) of patients undergoing surgical treatment for degenerative meniscus lesions or acute meniscus tears (including meniscectomy, repair, or reconstruction). Prevention programs, non-operative treatment of acute tears and degenerative lesions, return to sports and patient-reported outcome measures (PROMS) will be presented in a part-II article. Methods This consensus followed ESSKA “formal consensus” methodology. For this combined ESSKA (European Society for Sports Traumatology and Arthroscopy), AOSSM (American Orthopedic Society for Sports Medicine), ASSPT (American Academy of Sports Physical Therapy) initiative, 67 experts (26 in the steering group and 41 in the rating group) from 14 countries (USA and 13 European countries) including orthopedic surgeons, sports medicine doctors and physiotherapists were involved. Steering group members established guiding questions, searched the literature, proposed statements. Rating group members assessed the statements according to a Likert scale and provided grades of recommendations reaching final agreement about rehabilitation of the knee after meniscus surgery. Final documents were then assessed by a peer review group to adress the geographical adaptability. Results The overall level of evidence of the literature was low. Of the 19 questions (leading to 29 statements), one received a grade A of recommendation, two a grade B, nine a grade C and 17 a Grade D. Nevertheless, the mean median rating of all questions was 8.2/9 (9 being the highest rating on a scale of 1-9) and the global mean rating was 8.4+/-0.2, indicating a high agreement. Rehabilitation depends on the type of lesion, the treatment performed and is the same after medial or lateral meniscus surgery. Rehabilitation after meniscectomy should follow a criterion-based rehabilitation protocol, based on milestones rather than a time-based protocol. After meniscus repair and reconstruction, rehabilitation should be progressed according to both time and criterion-based milestones. Conclusion Rehabilitation after meniscus surgery is a debated topic that may influence surgical outcomes if not optimally performed. This international formal consensus established clear, updated, and structured recommendations for both surgeons and physiotherapists treating patients after meniscus surgery. Level of Evidence I, Consensus.
Increasing Fluconazole Resistance in Candida parapsilosis : A 10-Year Analysis of Blood Culture Isolates at a US Reference Laboratory (2015–2024)
McHugh, Jack , Chesdachai, Supavit , Dunsirn, Murray, Wengenack, Nancy L. , Vergidis, Paschalis , Wengenack, Nancy, McHugh, Jack , Vergidis, Paschalis , Chesdachai, Supavit

The Journal of Infectious Diseases | May 12, 2025 | Volume: 232 | Issue: 5 | Pages: 1198-1202

10.1093/infdis/jiaf249 | PMID 40360931 Get It

Abstract Antifungal susceptibility testing among 1740 Candida parapsilosis blood isolates submitted to a United States reference laboratory (2015–2024) revealed a significant increase in fluconazole resistance from 8.2% to 20.3% (odds ratio [OR] per year, 1.13 [95% confidence interval {CI}, 1.06–1.20]; P < .001), with notable acceleration since 2021. Voriconazole resistance remained stable over this period. Micafungin resistance was rare, but intermediate susceptibility significantly increased, especially after 2021 (OR per year, 1.42 [95% CI, 1.25–1.63]; P < .001). These findings highlight important recent shifts in antifungal susceptibility among C parapsilosis isolates, emphasizing the need for ongoing surveillance and stewardship.
Arrhythmogenic cardiomyopathy diagnosis and management: a systematic review of clinical practice guidelines and recommendations with insights for future research
Iezzi, Lorena , Sorella, Anna, Galanti, Kristian , Gallina, Sabina , Lopes, Luís R. , Ricci, Fabrizio , Khanji, Mohammed Y , Chahal, Anwar A, Bauce, Barbara , Ricci, Fabrizio , Khanji, Mohammed Yunus , Lopes, Luis Rocha , Chahal, C. Anwar A. , Cipriani, Alberto , Providência, Rui , Ricci, Fabrizio

European Heart Journal - Quality of Care and Clinical Outcomes | May 12, 2025 | Volume: 11 | Issue: 7 | Pages: 1033-1069

10.1093/ehjqcco/qcaf029 | PMID 40386976 Get It

Abstract Arrhythmogenic cardiomyopathy (ACM) is addressed in international guidelines and expert consensus statements. To assist clinicians in their routine practice and support decision-making, we performed a systematic review of the most relevant guidelines and recommendations for ACM diagnosis and management. Our search, covering MEDLINE, EMBASE, and resources from scientific societies over the last 10 years, identified two guidelines and three consensus statements that met rigorous inclusion criteria for detailed analysis. In the examined documents, key areas of agreement included the critical role of cardiac imaging for initial diagnosis and ongoing monitoring, genetic testing in index patients, ventricular arrhythmia management, catheter ablation indications, heart failure treatment strategies, and exercise recommendations. However, significant differences were found in definitions and diagnostic criteria for ACM, interpretation of phenocopies, management of family members, and criteria for implantable cardioverter defibrillator implantation. Additional discrepancies emerged regarding the role of multidisciplinary teams, non-cardiac surgical considerations, atrial fibrillation management, and reproductive issues. Crucially, there remain considerable gaps in evidence, especially in areas such as the management and follow-up of patients with potential or borderline ACM diagnoses, as well as the care of their relatives. The clinical implications of genetic findings, along with the clinical management of left-dominant, biventricular phenotypes, and hot phases of disease, are also insufficiently addressed. Furthermore, a critical shortfall is the lack of externally validated risk assessment tools to guide clinical decision-making. Bridging these gaps could help guiding future research and guideline development towards improving patient outcomes.
Evolving Strategies in the Detection and Management of Left Ventricular Thrombus: A Clinical Summary
Abdelnabi, Mahmoud , Ibrahim, Ramzi, Saleh, Yehia , Ibrahim, Ramzi, Pham, Hoang Nhat , Almaghraby, Abdallah Mostafa

Current Cardiology Reviews | May 12, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.2174/011573403x364065250429095440 | PMID 40353464 Get It

Recent advancements have emerged in understanding the epidemiology and optimal therapeutic options for left ventricular thrombi (LVT). With early percutaneous interventions in acute myocardial infarction, the prevalence of LVT has decreased. However, the best strategies for prevention, risk stratification, and management remain unclear, especially among nonischemic cardiomyopathy disorders. This review outlines these advancements and provides an overview of the diagnostic and therapeutic implications of LVT in ischemic and non-ischemic cardiomyopathies. Significant gaps in the current evidence persist, particularly regarding the optimal timing for LVT screening and the need for prophylactic anticoagulation, highlighting opportunities for prospective cohort studies. Furthermore, a better understanding of the unique risk factors that contribute to increased LVT risk would lead to more comprehensive algorithms that may quantify the risk of LVT development, aiding in developing preventive strategies targeted at reducing rates of LVT. Until more definitive evidence is available, clinicians should custom LVT screening, preventive measures, and management strategies based on individual patient risk factors.